PARIS and CHICAGO, Oct. 10, 2024
New MammoScreen® AI delivers a comprehensive suite of features including breast density and pre-reporting, creating the ultimate radiologist companion.
Advertisement
PARIS and CHICAGO, Oct. 10, 2024 /PRNewswire/ -- Therapixel, maker of MammoScreen, announces today that it has received two new FDA 510(k) clearances, resulting in the release of its most comprehensive breast cancer screening AI. With a set of powerful new features, MammoScreen goes beyond suspicious lesion detection and characterization and incorporates AI into all areas of the breast imaging workflow.
Advertisement
The new version of MammoScreen maintains the consistent and actionable MammoScreen Score™ while increasing the radiologist's sensitivity and specificity. This newly cleared full AI-suite provides the following powerful new features which will considerably improve radiologists' workflow:
These new features, now available for clinical use, will help radiologists read faster and more confidently, thus delivering results to women in a more timely and assured manner. The new release of MammoScreen helps make the entire organization better.
"Therapixel has consistently empowered radiologists to excel, ensuring women receive reassurance faster and with greater confidence," said Matthieu Leclerc-Chalvet, CEO of Therapixel. "These major clearances and releases elevate MammoScreen to a comprehensive suite, assisting radiologists at every step of the breast cancer screening workflow, and providing a service unmatched in the industry. With these new features, radiologists can double their reading time savings compared to the previous version. Radiologists will appreciate the reduced fatigue, administrators the improved efficiency and care consistency, and the IT team the seamless one-time installation. We're proud to launch this new version of MammoScreen, once again delivering unparalleled value to radiologists and patients."
About Breast Cancer
Breast cancer is the most common cancer among women worldwide, with an estimated 2.3 million new cases diagnosed each year. It accounts for nearly 1 in 4 cancer diagnoses in women. Early detection is critical, as it significantly increases survival rates; when caught at an early stage, the five-year survival rate exceeds 90%. However, challenges remain, including disparities in access to screening and care, as well as the need for improved diagnostic accuracy. Continuous advancements in technology and screening methods are vital in the fight against breast cancer.
About Therapixel
Therapixel is a leading medical imaging company specializing in AI-driven solutions for radiology. With a focus on breast cancer screening, Therapixel empowers radiologists with cutting-edge technology to improve diagnostic accuracy, enhance workflow efficiency, and ultimately deliver better patient outcomes. Committed to innovation and quality, Therapixel continually pushes the boundaries of AI to support healthcare professionals in detecting cancers earlier and more effectively.
Press Contact
David Troy
[email protected]
+1 773 316 6611
View original content to download multimedia:https://www.prnewswire.com/news-releases/therapixel-announces-two-new-fda-clearances-for-its-most-advanced-breast-cancer-screening-ai-solution-302273381.html
SOURCE Therapixel
